Bristol-Myers Squibb Makes First Investment In European VC Fund
This article was originally published in Scrip
Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.
You may also be interested in...
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.